These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22444787)

  • 41. Calculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapies.
    Mills EJ; Thorlund K; Ioannidis JP
    J Clin Epidemiol; 2012 Dec; 65(12):1282-8. PubMed ID: 22981250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Smoke and mirrors: Limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis.
    Zakaria M
    Mult Scler Relat Disord; 2015 May; 4(3):187-91. PubMed ID: 26008935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preventing multiple sclerosis?
    Ebers GC
    Lancet; 2001 May; 357(9268):1547. PubMed ID: 11377638
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials.
    Costello J; Njue A; Lyall M; Heyes A; Mahler N; Philbin M; Nazareth T
    Degener Neurol Neuromuscul Dis; 2019; 9():55-78. PubMed ID: 31308790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: A systematic review.
    Li R; Sun X; Shu Y; Mao Z; Xiao L; Qiu W; Lu Z; Hu X
    Mult Scler Relat Disord; 2017 Feb; 12():23-28. PubMed ID: 28283101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Network meta-analyses: Interest and limits in oncology].
    Ribassin-Majed L; Pignon JP; Michiels S; Blanchard P
    Bull Cancer; 2016 Mar; 103(3):289-93. PubMed ID: 26917469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.
    Huang D
    Neurosci Bull; 2015 Dec; 31(6):745-54. PubMed ID: 26480875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Placebo power.
    Knox KB; Kelly ME
    Tech Vasc Interv Radiol; 2012 Jun; 15(2):150-2. PubMed ID: 22640504
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
    Tur C; Kalincik T; Oh J; Sormani MP; Tintoré M; Butzkueven H; Montalban X
    Neurology; 2019 Oct; 93(18):793-809. PubMed ID: 31591277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
    Papadopoulos D; Gklinos P; Psarros G; Drellia K; Delicha EM; Friede T; Mitsikostas DD; Nicholas RS
    J Neurol; 2022 Jun; 269(6):3226-3237. PubMed ID: 35066607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Towards a european network for multiple sclerosis trials (ENMST).
    Kappos L; Polman C; Thompson AJ; Duda P; Clanet M; Comi G; Hartung HP; Montalban X
    Mult Scler; 2003 Dec; 9(6):627-9. PubMed ID: 14664478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The natural history of multiple sclerosis: implications for trial design.
    Wingerchuk DM; Weinshenker BG
    Curr Opin Neurol; 1999 Jun; 12(3):345-9. PubMed ID: 10499179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    Tryfonos C; Chrysafi M; Vadikolias K; Berberoglou L; Vorvolakos T; Dimoliani S; Tsourouflis G; Kontogiorgis C; Antasouras G; Giaginis C
    J Neurol; 2024 Apr; 271(4):1536-1570. PubMed ID: 38177875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating a treatment effect: Choosing between relative and absolute measures.
    Sormani MP; Bruzzi P
    Mult Scler; 2017 Feb; 23(2):197-200. PubMed ID: 27207463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using Mnemonic in Management of Multiple Sclerosis.
    Toufic El Hussein M; Wong A
    J Neurosci Nurs; 2022 Feb; 54(1):48-51. PubMed ID: 35007262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Ghezzi A
    Mult Scler; 2017 Jun; 23(7):1042-1043. PubMed ID: 28273766
    [No Abstract]   [Full Text] [Related]  

  • 57. Superlative use within news articles relating to therapies for multiple sclerosis.
    Ferrell M; Ferrell S; Ottwell R; Johnson J; Vassar M
    Mult Scler Relat Disord; 2021 Apr; 49():102736. PubMed ID: 33444956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Considering the Future of Pediatric Multiple Sclerosis Trials After the CONNECT Open-Label Randomized Trial.
    Abdel-Mannan O; Ciccarelli O; Hacohen Y
    JAMA Netw Open; 2022 Sep; 5(9):e2230451. PubMed ID: 36169961
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluation of Methods for the Inclusion of Real World Evidence in Network Meta-Analysis - A Case Study in Multiple Sclerosis.
    Jenkins D; Czachorowski M; Bujkiewicz S; Dequen P; Jonsson P; Abrams KR
    Value Health; 2014 Nov; 17(7):A576. PubMed ID: 27201933
    [No Abstract]   [Full Text] [Related]  

  • 60. Standards for randomized controlled trials of efficacy of psychological treatments.
    Mohr DC
    World Psychiatry; 2024 Jun; 23(2):286-287. PubMed ID: 38727052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.